In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet

Authors :: Gaetano Santulli
Santulli, Gaetano
Source :: Annals of Internal Medicine. 172:JC6
Publication Year :: 2020
Publisher :: American College of Physicians, 2020.
Abstract: Source Citation Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103-13. 31475793

Tools